VRAX
NASDAQVirax Biolabs Group Limited
$6.36
+3.18 (+100.00%)
2026-07-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$2.5M
P/E Ratio
N/A
52W Low
52W High
$0.10
$13.17
Volume
71.4M
Analyst Rating
Hold
Target: $4
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $1
Avg: $4
High: $25
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary ...
Employees
19
Website
viraxbiolabs.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $6K | -97344.8% | -$6.1M | -$4.0M |
| 2024 | $156K | -4153.3% | -$6.7M | -$5.1M |
| 2023 | $9K | -66963.7% | -$5.5M | -$4.0M |
| 2022 | N/A | N/A% | -$1.7M | -$809K |
| 2021 | $124K | -520.5% | -$651K | -$590K |
| 2025 Q3 | $2K | -160788.2% | -$2.3M | -$2.8M |
| 2025 Q2 | $1K | -238316.8% | -$3.3M | -$2.1M |
| 2025 Q1 | N/A | N/A% | N/A | N/A |
| 2024 Q3 | $5K | -58124.2% | -$2.8M | -$1.7M |
| 2024 Q2 | $80K | -4742.6% | -$3.8M | -$2.3M |
| 2024 Q1 | N/A | N/A% | N/A | N/A |
| 2023 Q3 | $76K | -3537.5% | -$2.9M | -$2.7M |
| 2023 Q1 | $3K | -153237.8% | -$4.0M | -$1.7M |